DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: canakinumab
Drug: MBG453
Drug: NIS793

First Posted Date: 2021-03-23

Last Posted Date: 2025-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT04810611

Locations: 🇺🇸
The Ohio State University Wexner Medical Center ., Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital ., Boston, Massachusetts, United States
🇺🇸
City Of Hope National Med Center Oncology, Duarte, California, United States

and more 3 locations

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: sabatolimab
Drug: azacitidine
Drug: venetoclax

First Posted Date: 2021-03-23

Last Posted Date: 2025-04-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT04812548

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

Phase 3

Completed

Conditions: Elevated Low Density Lipoprotein Cholesterol
Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Disease Risk Equivelents

Interventions: Behavioral: Behavioural Support
Drug: Inclisiran
Drug: Background lipid lowering therapy

First Posted Date: 2021-03-19

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 892

Registration Number: NCT04807400

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

Phase 2

Terminated

Conditions: Presbyopia

Interventions: Drug: UNR844
Drug: Placebo

First Posted Date: 2021-03-19

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 234

Registration Number: NCT04806503

Locations: 🇯🇵
Novartis Investigative Site, Shinjuku ku, Tokyo, Japan

Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Placebo
Drug: Eltrombopag

First Posted Date: 2021-03-15

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT04797000

Locations: 🇯🇵
Novartis Investigative Site, Yamagata, Japan

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Phase 2

Completed

Conditions: Leukemia, Chronic Myelogenous

Interventions: Other: best available treatment
Drug: asciminib

First Posted Date: 2021-03-12

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT04795427

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Phase 2

Terminated

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Biological: Canakinumab
Other: Placebo

First Posted Date: 2021-03-12

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT04795466

Locations: 🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States
🇺🇸
SUNY at Stony Brook, Stony Brook, New York, United States
🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Phase 4

Completed

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Drug: BAF312
Drug: Baseline disease modifying therapies (DMTs)
Biological: BNT162
Biological: mRNA-1273

First Posted Date: 2021-03-11

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04792567

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Ofatumumab
Drug: First line DMT

First Posted Date: 2021-03-09

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT04788615

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Spain

Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia

Phase 1

Terminated

Conditions: Amblyopia

Interventions: Device: Patching of the sound eye
Device: Binocular video games

First Posted Date: 2021-03-05

Last Posted Date: 2023-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT04784390

Locations: 🇨🇦
Novartis Investigative Site, Waterloo, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy